We present KCL-HO-1i, a small-molecule therapeutic that overcomes the limitations of current HO-1 inhibitors for oncology indications and offers an orally bioavailable, non-toxic small-molecule drug candidate to target the pro-tumorigenic function of PvTAMs in cancer, specifically to alleviate resistance to standard-of-care chemotherapy. Here, HMOX1 is linked to cancer.